Esketamine, sold under the brand names Spravato (for depression) and Ketanest (for anesthesia) among others, is the S(+) enantiomer of ketamine. It is...

the (R)-(−) enantiomer of ketamine. Similarly to racemic ketamine and esketamine, the S(+) enantiomer of ketamine, arketamine is biologically active; however...

"painkiller." Following the 2019 approval of the ketamine enantiomer esketamine by the European Medicines Agency and FDA for use with treatment-resistant...

ketamine – esketamine commercially sold as Spravato – was approved as an antidepressant by the European Medicines Agency in 2019. Esketamine was approved...

an atypical agent in that it appears not to do this. In August 2020, esketamine (JNJ-54135419) was approved by the U.S. Food and Drug Administration (FDA)...

mass: 237.0920 u) may refer to: Ketamine Arketamine, or (R)-(−)-ketamine Esketamine, also known as (S)-ketamine or S(+)-ketamine This set index page lists...

receptor positive allosteric modulator – approved for postpartum depression Esketamine (Spravato) – non-competitive NMDA receptor antagonist, other actions Gepirone...

neuronal atrophy where neuroplasticity can elicit beneficial effects. Esketamine, sold under the brand name Spravato and produced by Janssen Pharmaceuticals...

disorder, and major depressive disorder. Spravato, a nasal spray form of esketamine, was approved by the FDA in 2019 for use in treatment-resistant depression...

March 2019, the Food and Drug Administration approved Janssen's Spravato (esketamine nasal spray) for treatment-resistant major depressive disorder. This marked...